Earlier this week, Neptune Technologies & Bioressources Inc. announced the filing of new lawsuits in the U.S. against Enzymotec Ltd. and other key producers and branded companies following the grant of U.S. patent No. 8,278,351 (the "'351 patent").
“Neptune's aggressive approach is not warranted given their IP portfolio" says Ariel Katz Enzymotec's CEO. "We believe that the '351 patent, similarly to a related patent which was revoked in Europe following an opposition, is invalid, unenforceable and therefore not infringed by Enzymotec Ltd., Enzymotec USA or its customers" concludes Dr. Katz .
“Our message to our extensive and loyal U.S. customer base is simple: Enzymotec will continue to defend its leading position in this market and will support its customers. We continue to invest resources in supporting our rapid growth both through capacity expansion and through human clinical trials. We are certain those consistent actions will lead to further establishing KREAL™ image and the superior krill oil quality and potency obtained through our exclusive MSO™ technology,” says Elzaphan Hotam, CEO of Enzymotec USA.